Ahmad Halwani, MD
Medical Oncology · Salt Lake City, UTNPI 1447460274
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,531 of the $1,531 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, F. Hoffmann-la Roche AG. That places this record below the midpoint for medical oncology clinicians in UT, where the typical reported total is $2,800.
Across 5 payments — averaging $306.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$2K
Across 173 payments — averaging $13,280 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.2M
- Amgen$313K
- Bayer$296K
- Merck$156K
- Pharmacyclics LLC, An Abbvie Company$94K
- AbbVie$88K
- plus $164K from 5 others
What the payments were for
- Speaking & faculty fees$1,531100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 5 | $1,531 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$724
- Venclexta$480
- Non-Covered Product$327
How this compares
$1,531 in reported general payments places this provider in the 35th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 49 | $778,906 |
| VenclextaVenetoclax | 40 | $555,376 |
| CalquenceAcalabrutinib Maleate | 36 | $520,270 |
| EliquisApixaban | 11 | $7,774 |
| Acyclovir | 29 | $669 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Salt Lake City
- Bradley HunterSalt Lake City$263K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
- Nitin ChandramouliSalt Lake City$19K
- Kenneth GrossmannSalt Lake City$15K
- Manish KohliSalt Lake City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.